Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.52 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL498155 | 0.97 | TSHR (0.56) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL20198601 | 0.97 | TSHR (0.56) | CYP1A2USP2ALDH1A1LMNATSHR | |
| Hydrochloric Acid SCHEMBL3705397 | 0.97 | CYP1A2 (0.50) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL20104809 | 0.97 | TSHR (0.56) | CYP1A2USP2ALDH1A1LMNATSHR | |
| Hydrochloric Acid SCHEMBL7609840 | 0.95 | TSHR (0.54) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL430341 | 0.95 | — | — | |
| SCHEMBL4115624 | 0.89 | — | — | |
| Sulfuric Acid SCHEMBL4208350 | 0.89 | CYP1A2 (0.48) | CYP1A2USP2ALDH1A1LMNATSHR | |
| Hydrochloric Acid SCHEMBL16666607 | 0.86 | — | — | |
| Trifluoroacetic Acid SCHEMBL22342626 | 0.85 | USP2 (0.46) | CYP1A2USP2ALDH1A1LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 142 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10017481-B2 | Conformationally constrained, fully synthetic macrocyclic compounds | POLYPHOR AG (CH) | 2018-07-10 | — | — | US | claimed |
| EP-2836485-B1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2018-01-10 | — | — | EP | claimed |
| US-9695191-B2 | Conformationally constrained, fully synthetic macrocyclic compounds | POLYPHOR AG (CH) | 2017-07-04 | — | — | US | claimed |
| EP-2499148-B1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2017-01-18 | — | — | EP | claimed |
| US-9512139-B2 | Conformationally constrained, fully synthetic macrocyclic compounds | POLYPHOR AG (CH) | 2016-12-06 | — | — | US | claimed |
| US-20150051183-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2015-02-19 | — | — | US | claimed |
| EP-2836485-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | Polyphor Ag (CH) | 2015-02-18 | — | — | EP | claimed |
| EP-2462147-B1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2014-11-12 | — | — | EP | claimed |
| WO-2013139697-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2013-09-26 | — | — | WO | claimed |
| CN-101466730-B | A process for the preparation of poly-alfa-glutamic acid andderivatives thereof | CELL THERAPEUTICS INC SEDE SEC | 2013-09-04 | — | — | CN | claimed |
| US-20120202821-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2012-08-09 | — | — | US | claimed |
| EP-2364991-A1 | A process for the preparation of poly-alfa-glutamic acid and derivatives thereof | Cell Therapeutics, Inc. - Sede Secondaria (IT) | 2011-09-14 | — | — | EP | claimed |
| US-20110196123-A1 | PROCESS FOR THE PREPARATION OF POLY-alpha-GLUTAMIC ACID AND DERIVATIVES THEREOF | CELL THERAPEUTICS, INC. (US) | 2011-08-11 | — | — | US | claimed |
| WO-2011014973-A2 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2011-02-10 | — | — | WO | claimed |
| CN-101466730-A | A process for the preparation of poly-alfa-glutamic acid andderivatives thereof | CELL THERAPEUTICS INC SEDE SEC (IT) | 2009-06-24 | — | — | CN | claimed |
| EP-2027145-A1 | A PROCESS FOR THE PREPARATION OF POLY-ALFA-GLUTAMIC ACID AND DERIVATIVES THEREOF | Cell Therapeutics, Inc. - Sede Secondaria (IT) | 2009-02-25 | — | — | EP | claimed |
| EP-1932852-A1 | Novel taxane related peptides and uses thereof | Campiani, Giuseppe (IT) | 2008-06-18 | — | — | EP | claimed |
| US-20080051603-A1 | Process for the preparation of poly-alpha-glutamic acid and derivatives thereof | CELL THERAPEUTICS, INC. (US) | 2008-02-28 | — | — | US | claimed |
| WO-2007144140-A1 | A PROCESS FOR THE PREPARATION OF POLY-ALFA-GLUTAMIC ACID AND DERIVATIVES THEREOF | CELL THERAPEUTICS INC. - SEDE SECONDARIA (IT) | 2007-12-21 | — | — | WO | claimed |
| EP-1867657-A1 | Process for the preparation of poly-a-glutamic acid and derivatives thereof | Cell Therapeutics Europe S.R.L. (IT) | 2007-12-19 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202821-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | HTR2B, MC1R, HTR1A | CYP1A2 882/4885USP2 4325/4885ALDH1A1 4268/4885 |
| US-10017481-B2 | Conformationally constrained, fully synthetic macrocyclic compounds | CTSE, CTSB, CTSS | CYP1A2 3680/4885USP2 2386/4885ALDH1A1 4415/4885 |
| US-20080051603-A1 | Process for the preparation of poly-alpha-glutamic acid and derivatives thereof | GLUL, QPCT, GABRP | CYP1A2 4456/4885USP2 456/4885ALDH1A1 1318/4885 |
| US-20150051183-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | CTSE, CTSB, CTSS | CYP1A2 3680/4885USP2 2386/4885ALDH1A1 4415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.